Skip to Content

FDA Approves Sutent for Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

Sutent is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs). Sutent is indicated for the treatment of patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer.

Posted: January 2006

Related Articles:

Sutent (sunitinib malate) FDA Approval History